Skip to main content
SpringerLink
Log in

Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Malignant peritoneal mesothelioma (MPM) is a rare diagnosis with a dismal prognosis if untreated. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is shown to significantly improve survival. Our institution is uniquely positioned to report long-term outcomes in MPM with CRS-HIPEC, due to our robust peritoneal surface disease program existing over the past three decades.

Methods

Our prospectively maintained, single-institution database of CRS-HIPEC cases was reviewed, identifying 111 consecutive patients with MPM over 28 years (1993–2021). Prognostic, operative, and pathologic factors were reviewed. Overall survival (OS) and conditional survival (CS) analyses were performed.

Results

The average age was 55.1 years; 58.6% of patients were male; 17 of 111 patients (15.3%) had a second CRS-HIPEC. At first CRS-HIPEC, the average PCI score was 18.7, and the perfusate drugs were platinum-based (72.1%) and mitomycin C (27.9%). The resection status at first CRS-HIPEC was R2a (46.4%), followed by R0-1 (29.1%), and R2b-c (24.5%). Median OS was 3.3 years for the entire cohort, with 75th and 25th percentiles at 10.7 months and 10.6 years. Median CS was improved if patients survived to the 1-year postoperative mark (4.9 years, p < 0.01) and trended toward further improvement with each passing year. If 3-year postoperative survival was achieved, the median CS improved to 6.1 years.

Conclusions

This represents one of the largest and lengthiest, single-center, longitudinal, case series of peritoneal mesothelioma treated with CRS-HIPEC. The OS suggests efficacy for CRS-HIPEC for MPM. Long-term survival improves significantly after patients achieve the 1-year, postoperative mark.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–6.

    Article  CAS  PubMed  Google Scholar 

  2. Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2005;12:910–8.

    Article  PubMed  Google Scholar 

  3. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.

    Article  CAS  PubMed  Google Scholar 

  4. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.

    Article  PubMed  Google Scholar 

  5. Winslow DJ, Taylor HB. Malignant peritoneal mesotheliomas: a clinicopathological analysis of 12 fatal cases. Cancer. 1960;13:127–36.

    Article  CAS  PubMed  Google Scholar 

  6. Karakousis CP, Seddiq M, Moore R. Malignant mesotheliomas and chemotherapy. J Surg Oncol. 1980;15:181–5.

    Article  CAS  PubMed  Google Scholar 

  7. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  CAS  PubMed  Google Scholar 

  8. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–91.

    Article  CAS  PubMed  Google Scholar 

  9. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  10. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:2720–7.

    Article  PubMed  Google Scholar 

  11. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43:1228–35.

    Article  CAS  PubMed  Google Scholar 

  12. Kepenekian V, Peron J, You B, et al. Non-resectable malignant peritoneal mesothelioma treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a cohort study. Ann Surg Oncol. 2022;29:2104–13.

    Article  PubMed  Google Scholar 

  13. Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015;41:1373–8.

    Article  CAS  PubMed  Google Scholar 

  14. Wong JF, Tan GH, Wang W, Soo KC, Teo MC. Repeat cytoreductive surgery and HIPEC for peritoneal surface malignancy and peritoneal carcinomatosis. World J Surg. 2015;39:1578–83.

    Article  PubMed  Google Scholar 

  15. Konstantinidis IT, Levine EA, Chouliaras K, Russell G, Shen P, Votanopoulos KI. Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;116:741–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Valenzuela CD, Levine EA, Mangieri CW, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: A 30-year institutional experience. Ann Surg Oncol. 2022;29:3436–45.

    Article  PubMed  Google Scholar 

  17. Ali YM, Sweeney J, Shen P, et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with peritoneal mesothelioma. Ann Surg Oncol. 2020;27:117–23.

    Article  PubMed  Google Scholar 

  18. Aydin N, Sardi A, Milovanov V, et al. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: Experience of a peritoneal surface malignancy center. Am Surg. 2015;81:1253–9.

    Article  PubMed  Google Scholar 

  19. Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35:980–5.

    Article  CAS  PubMed  Google Scholar 

  20. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–12.

    Article  CAS  PubMed  Google Scholar 

  21. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181–8.

    Article  PubMed  Google Scholar 

  22. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8.

    Article  PubMed  Google Scholar 

  23. Arjona-Sanchez A, Aziz O, Passot G, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2021;47:1420–6.

    Article  CAS  PubMed  Google Scholar 

  24. Deraco M, Nizri E, Glehen O, et al. Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. Eur J Surg Oncol. 2019;45:371–5.

    Article  PubMed  Google Scholar 

  25. Cashin PH, Jansson Palmer G, Asplund D, Graf W, Syk I. Peritoneal mesothelioma in Sweden: A population-based study. Cancer Med. 2019;8:6468–75.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Roife D, Powers BD, Zaidi MY, et al. CRS/HIPEC with major organ resection in peritoneal mesothelioma does not impact major complications or overall survival: A retrospective cohort Study of the US HIPEC collaborative. Ann Surg Oncol. 2020;27:4996–5004.

    Article  PubMed  Google Scholar 

  27. Kepenekian V, Peron J, Goere D, et al. Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: results from a large multicentric cohort. Int J Hyperther. 2021;38:805–14.

    Article  CAS  Google Scholar 

  28. Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018;25:667–73.

    Article  PubMed  Google Scholar 

  29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  CAS  PubMed  Google Scholar 

  30. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573–85.

    Article  PubMed  Google Scholar 

  31. Fernandez-Trigo V, Stuart OA, Stephens AD, Hoover LD, Sugarbaker PH. Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Cancer Treat Res. 1996;81:51–61.

    Article  CAS  PubMed  Google Scholar 

  32. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    Article  CAS  PubMed  Google Scholar 

  33. Bayes T. An essay towards solving a problem in the doctrine of chances. Phil Trans R Soc. 53:370–418 1763: By the late Rev. Mr. Bayes, F. R. S. communicated by Mr. Price, in a letter to John Canton, A. M. F. R. S.

  34. Zhong Q, Chen QY, Li P, et al. Prediction of conditional probability of survival after surgery for gastric cancer: A study based on Eastern and Western large data sets. Surgery. 2018;163:1307–16.

    Article  PubMed  Google Scholar 

  35. Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol. 2013;20:1623–30.

    Article  PubMed  Google Scholar 

  36. Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003;21:3035–40.

    Article  PubMed  Google Scholar 

  37. Valenzuela CD, Mangieri CW, Garland-Kledzik M, et al. Timing of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for recurrent low-grade appendiceal mucinous neoplasms. Ann Surg Oncol. 2022;29:3422–31.

    Article  PubMed  Google Scholar 

  38. van Kooten JP, Dietz MV, Guchelaar NAD, et al. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO. BMJ Open. 2022;12:e062907.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kyang LS, Alzahrani NA, Valle SJ, Rahman MK, Arrowaili A, Liauw W, Morris DL. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. J Surg Oncol. 2019;120:794–802.

    PubMed  Google Scholar 

  40. Valenzuela CD, Moaven O, Gawdi R, et al. Repeat hepatectomy outcomes for colorectal liver metastases from an international multicenter collaborative. HPB. 2021;23:S635.

    Article  Google Scholar 

  41. Hung YP, Dong F, Torre M, Crum CP, Bueno R, Chirieac LR. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol. 2020;33:2269–79.

    Article  CAS  PubMed  Google Scholar 

  42. Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29:14–24.

    Article  CAS  PubMed  Google Scholar 

  43. Lund-Andersen C, Nakken S, Nygard S, et al. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. Cold Spring Harb Mol Case Stud. 2019. https://doi.org/10.1101/mcs.a003566. (Print 2019 Apr).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-21200-8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Supported in part by: Wake Forest University Comprehensive Cancer Center Biostatistics shared resource funded via the NCI Grant award P30CA012197.

Author information

Authors and Affiliations

  1. Surgical Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA

    Cristian D. Valenzuela MD, Ian B. Solsky MD, Richard A. Erali MD, Steven D. Forsythe BS, MS, Christopher W. Mangieri MD, Bigyan B. Mainali MD, Kathleen C. Perry BS, Konstantinos I. Votanopoulos MD, PhD, Perry Shen MD & Edward A. Levine MD

  2. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Gregory Russell BS, MS

Authors
  1. Cristian D. Valenzuela MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian B. Solsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard A. Erali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven D. Forsythe BS, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher W. Mangieri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bigyan B. Mainali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gregory Russell BS, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kathleen C. Perry BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Konstantinos I. Votanopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Perry Shen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Edward A. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward A. Levine MD.

Ethics declarations

Disclosure

The Authors have nothing to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work was presented at the 2022 SSO International Conference on Surgical Cancer Care, Featuring Advanced Cancer Therapies, Dallas, TX.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 103 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valenzuela, C.D., Solsky, I.B., Erali, R.A. et al. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center. Ann Surg Oncol 30, 2666–2675 (2023). https://doi.org/10.1245/s10434-022-13061-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-13061-3

Search

Navigation